IRVINE, Calif., March 09, 2023 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company will present a preclinical poster at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting, being held in Salt Lake… Continue reading Reneo Pharmaceuticals to Present Preclinical Mavodelpar (REN001) Data at the Society for Inherited Metabolic Disorders Annual Meeting 2023
